Details

Autor(en) / Beteiligte

• Liu, Sean T. H.
• Lin, Hung-Mo
• Baine, Ian
• Wajnberg, Ania
• Gumprecht, Jeffrey P.
• Rahman, Farah
• Rodriguez, Denise
• Tandon, Pranai
• Bassily-Marcus, Adel
• Bander, Jeffrey
• Sanky, Charles
• Dupper, Amy
• Zheng, Allen
• Nguyen, Freddy T.
• Amanat, Fatima
• Stadlbauer, Daniel
• Altman, Deena R.
• Chen, Benjamin K.
• Krammer, Florian
• Mendu, Damodara Rao
• Firpo-Betancourt, Adolfo
• Levin, Matthew A.
• Bagiella, Emilia
• Casadevall, Arturo
• Cordon-Cardo, Carlos
• Jhang, Jeffrey S.
• Arinsburg, Suzanne A.
• Reich, David L.
• Aberg, Judith A.
• Bouvier, Nicole M.

Titel

Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study

Ist Teil von

• Nature medicine, 2020-11, Vol.26 (11), p.1708-1713

Ort / Verlag

New York: Nature Publishing Group US

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments 1 . Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. These antibodies, when transfused into patients infected with SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before patients have mounted their own humoral immune responses 2 , 3 . Virus-specific antibodies from recovered persons are often the first available therapy for an emerging infectious disease, a stopgap treatment while new antivirals and vaccines are being developed 1 , 2 . This retrospective, propensity score–matched case–control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe or life-threatening COVID-19 at The Mount Sinai Hospital in New York City. Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versus 28.2% of propensity score–matched controls who were hospitalized with COVID-19 (adjusted odds ratio (OR), 0.86; 95% confidence interval (CI), 0.75–0.98; chi-square test P value = 0.025). Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13–0.89; chi-square test P  = 0.027). Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed. Convalescent plasma for treatment of hospitalized patients with COVID-19 is associated with improved survival in a retrospective comparison with matched controls, supporting further study in randomized controlled trials.